# A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

Study · id `cardio:ct-nct05884866` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05884866](<https://clinicaltrials.gov/study/NCT05884866>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05884866

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT05884866. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2025-12-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT05884866, source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)
- Started: 2023-07-13 (actual) (ClinicalTrials.gov record NCT05884866, source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)
- Primary completion: 2025-12-29 (actual) (ClinicalTrials.gov record NCT05884866, source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)
- Completion: 2026-01-28 (actual) (ClinicalTrials.gov record NCT05884866, source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)
- Countries: France; Germany (ClinicalTrials.gov record NCT05884866, source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05884866-2026-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.
- Acronym: DapaBalci-Leap
- Condition: Chronic Renal Failure
- Condition: Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis
- Condition: Chronic Kidney Disease Stage 3
- Condition: Electrolyte and Fluid Balance Conditions
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Balcinrenone 50mg Capsule
- Intervention (Drug): Balcinrenone 100mg Capsule
- Intervention (Drug): Dapagliflozin matching Placebo
- Intervention (Drug): Balcinrenone 50mg matching Placebo
- Intervention (Drug): Balcinrenone 100mg matching Placebo
- Lead sponsor: Klinikum Nürnberg
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 1f7766ba8878209686df00b84ac66cb67e6bf19ab79a5d28dff48dff8f35657d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
